$0.2400
0.01818.16%
Last update: Nov 10, 4:08 AM
Traws Pharma Inc
TRAWNASDAQ
Traws Pharma fell 87.6% from $1.94 to $0.24, behind the S&P 500's +10.5%. Its worst day was Jun 15 (−41.0%), and its low came Nov 5 at $0.22.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.34 was reported on $0.00 revenue.
−17.3% · S&P 500 −1.7%
Traws Pharma shares fell 21.9%, while the S&P 500 rose 0.1%.
Story events cover the past 12 months · Times ET
−21.9% · S&P 500 +0.1%
The study was designed as an active-controlled comparator trial versus PAXLOVID™ (nirmatrelvir/ritonavir) and evaluated patient-reported symptom outcomes, safety, and real-world usability.
−36.4% · S&P 500 −1.1%
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpileUpdated clinical
+26.8% · S&P 500 −0.2%
Traws Pharma closed at its highest level of the year, 45.4% above where the year started.
+1.1% · S&P 500 +0.4%
EPS of $-0.71 missed the $-0.69 estimate on $0.00 revenue.
−1.6% · S&P 500 +0.2%
EPS of $-0.53 beat the $-0.56 estimate on $0.00 revenue.
+15.3% · S&P 500 −1.2%
Traws Pharma shares fell 41.0%, while the S&P 500 rose 1.8%.
−41.0%, the year's worst day · S&P 500 +1.8%
EPS of $-0.16 beat the $-0.40 estimate on $0.00 revenue.
−5.4% · S&P 500 −0.5%
Where it ended: a close of $0.24 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.20).
Nothing in the past 12 months.
All TRAW dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TRAW and SPY from Benzinga historical bars. Not investment advice.
